Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

January 10, 2012  6:30 – 9:00 p.m.

1. Executive Session  6:30 - 7:00
   ▪ Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes  7:00 - 7:05
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates  7:05 - 7:25
   ▪ Single Formulary
   ▪ Specialty Pharmacy
   ▪ Program Integrity Overview

4. Medical Director Update  7:25 - 7:30
   ▪ Clinical Programs Update
   ▪ Prescriber Comments

5. Follow-up Items from Previous Meetings  7:30 - 7:40
   ▪ Latuda®

6. RetroDUR  7:40 - 7:50
   ▪ Seroquel® Low Dose Initiative

7. Clinical Update: Drug Reviews  7:50 – 8:05
   (Public comment prior to Board action)

   Abbreviated Drug Reviews
   ▪ Horizant® (gabapentin enacarbil) ER Tablet
   ▪ Phoslyra® (calcium acetate) Oral Solution

   Full New Drug Reviews
   ▪ Xarelto® (rivaroxaban) Tablet

8. Therapeutic Drug Classes – Periodic Review  8:05 – 8:40
   (Public comment prior to Board action)

   Class review documents available on DVHA web site 1/10/2012 @ 12 Noon
   ▪ Anti-Diabetics
     ▪ DPP-4 Inhibitors
     ▪ Peptide Hormones: Amylinomimetics (Symlin®)
     ▪ Peptide Hormones: Incretin Mimetics
   ▪ Growth Hormone
- Multiple Sclerosis Medications
  - MS Biologic Response Modifiers
  - Potassium Channel Blockers (Ampyra®)
- Ophthalmics
  - Antibiotics
  - Antihistamines
  - NSAIDs
- Vaginal
  - Antibiotics
  - Antifungals (recommend not to manage aside from OTC management)

9. **New Managed Therapeutic Drug Classes** 8:40 – 8:40
   (Public comment prior to Board action)
   - None

10. **Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** 8:40 – 8:45
    (Public comment prior to Board action)
    - Atypical Antipsychotics: Long Acting Injectable Products

11. **General Announcements** 8:45– 8:55
    Selected FDA Safety Alerts
    - Gilenya® (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose
    - Multaq® (dronedarone): Drug Safety Communication - Increased Risk of Death or Serious Cardiovascular Events
    - Pradaxa® (dabigatran etexilate mesylate): Drug Safety Communication - Safety Review of Post-Market Reports of Serious Bleeding Events
    - Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: Drug Safety Communication - Use During Pregnancy and Potential Risk of Persistent Pulmonary Hypertension of the Newborn
    - Zocor® (simvastatin): Label Change - New Restrictions, Contraindications, and Dose Limitations

    Other
    - ALTITUDE Study of Aliskiren Terminated Early by Novartis

12. **Adjourn** 9:00